Tags

Type your tag names separated by a space and hit enter

Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
J Neurol. 2002 Sep; 249 Suppl 2:II25-9.JN

Abstract

Levodopa therapy is essential for patients in the advanced stages of Parkinson's disease. However, at early stages, DA agonist therapy has similar efficacy in the treatment of parkinsonism and a lower incidence of motor complications compared to levodopa therapy several years after the initiation of the therapy. The main factors causing motor complications have been speculated to be a severe reduction of dopaminergic nerve terminals because of disease progression, and a pulsatile stimulation of DA receptors using a drug with a short plasma half-life. DA agonists have longer plasma half-lifes than levodopa; therefore, they are expected to have a favorable effect on motor complications. Moreover, two clinical reports confirmed the potential neuroprotection by DA agonists. Although the patient's conditions should be considered in the selsction of a drug, DA agonist therapy is recommended as the initial therapy for Parkinson's disease.

Authors+Show Affiliations

Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0035, Japan.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

12375060

Citation

Kondo, Tomoyoshi. "Initial Therapy for Parkinson's Disease: Levodopa Vs. Dopamine Receptor Agonists." Journal of Neurology, vol. 249 Suppl 2, 2002, pp. II25-9.
Kondo T. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J Neurol. 2002;249 Suppl 2:II25-9.
Kondo, T. (2002). Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Journal of Neurology, 249 Suppl 2, II25-9.
Kondo T. Initial Therapy for Parkinson's Disease: Levodopa Vs. Dopamine Receptor Agonists. J Neurol. 2002;249 Suppl 2:II25-9. PubMed PMID: 12375060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. A1 - Kondo,Tomoyoshi, PY - 2002/10/11/pubmed PY - 2003/1/18/medline PY - 2002/10/11/entrez SP - II25 EP - 9 JF - Journal of neurology JO - J Neurol VL - 249 Suppl 2 N2 - Levodopa therapy is essential for patients in the advanced stages of Parkinson's disease. However, at early stages, DA agonist therapy has similar efficacy in the treatment of parkinsonism and a lower incidence of motor complications compared to levodopa therapy several years after the initiation of the therapy. The main factors causing motor complications have been speculated to be a severe reduction of dopaminergic nerve terminals because of disease progression, and a pulsatile stimulation of DA receptors using a drug with a short plasma half-life. DA agonists have longer plasma half-lifes than levodopa; therefore, they are expected to have a favorable effect on motor complications. Moreover, two clinical reports confirmed the potential neuroprotection by DA agonists. Although the patient's conditions should be considered in the selsction of a drug, DA agonist therapy is recommended as the initial therapy for Parkinson's disease. SN - 0340-5354 UR - https://www.unboundmedicine.com/medline/citation/12375060/Initial_therapy_for_Parkinson's_disease:_levodopa_vs__dopamine_receptor_agonists_ L2 - https://dx.doi.org/10.1007/s00415-002-1205-3 DB - PRIME DP - Unbound Medicine ER -